CD33 and acute myeloid leukemia: Gemtuzumab ozogamicin, a conjugate of humanized anti-CD33 monoclonal antibody covalently attached to the cytotoxic antitumor antibiotic calicheamicin, was firstly approved in 2000 under accelerated approval for treating CD33-positive acute myeloid leukemia (AML).